Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of Evolocumab (AMG145) on LDL-C in Subjects With Severe Familial Hypercholesterolemia

NCT01624142 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT01624142
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01624142 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of Evolocumab (AMG145) on LDL-C in Subjects With Severe Familial Hypercholesterolemia
Lead sponsor
Amgen
Phase
Phase 2/3
Overall status
Completed
Start date
June 1, 2012
Completion date
May 11, 2018
Enrollment
300 (actual)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

severe familial hypercholesterolemia